Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.78 Analyst target: $7.00 Upside: 797.09%
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company is headquartered in Emeryville, California.
See the full interactive analysis & chart →Informational only — not investment advice.